EUCTR2009-011793-14-SE进行中（未招募）不适用
Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. - LENAGEM-PANC
Karolinska Institute/Hospital0 个研究点开始时间: 2009年7月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic adenocarcinoma of the pancreas.
- •2. ECOG performance status of 0 or 1, see Appendix 1.
- •3. Life expectancy > 12 weeks.
- •4. Must understand and voluntarily sign an informed consent form.
- •5. Age > 18 years at the time of signing informed consent form.
- •6. Must be able to adhere to the study visit schedule and other protocol requirements.
- •7. Female subjects of childbearing potential† must:
- •a. Understand that the study medication is expected to have a teratogenic risk
- •b. Agree to use, and be able to comply with, effective contraception without interruption, 4 weeks before starting study drug, throughout study drug therapy (including dose interruptions) and for 4 weeks after the end of study drug therapy, even if she has amenorrhoea. This applies unless the subject commits to absolute and continued abstinence confirmed on a monthly basis. The following are effective methods of contraception*
- •i. Implant**
- •ii. Levonorgestrel-releasing intrauterine system (IUS)**
- •iii. Medroxyprogesterone acetate depot
- •iv. Tubal sterilization
- •v. Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses
- •vi. Ovulation inhibitory progesterone-only pills (i.e., desogestrel)
- •If not established on effective contraception, the female subject must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.
- •† A female subject or a female partner of a male subject is considered to have childbearing potential unless she meets at least one of the following criteria: Age =50 years and naturally amenorrhoeic for = 1 year (amenorrhea following cancer therapy does not rule out childbearing potential), premature ovarian failure confirmed by a specialist gynecologist, previous bilateral salpingo-oophorectomy or hysterectomy, XY genotype, Turner syndrome or uterine agenesis.
- •* Combined oral contraceptive pills are not recommended. If a subject was using combined oral contraception, she must switch to one of the methods above. The increased risk of VTE continues for 4 to 6 weeks after stopping combined oral contraception.
- •** Prophylactic antibiotics should be considered at the time of insertion particularly in subjects with neutropenia due to risk of infection. Copper-releasing intrauterine devices are generally not recommended due to the potential risks of infection at the time of insertion and menstrual blood loss which may compromise patients with neutropenia or thrombocytopenia.
- •c. Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 mIU/ml on the day of the study visit or in the 3 days prior to the study visit once the subject has been on effective contraception for at least 4 weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence. The test should ensure the subject is not pregnant when she starts treatment.
- •d. Agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks after the end of study treatment, except in the case of confirmed tubal sterilization. These pregnancy tests should be performed on the day of the study visit or in the 3 days prior to the study visit. This requirement also applies to women of childbearing potential who practice complete and continued abstinence.
- •e. Understand that even if she has amenorrhea,
排除标准
- •1. Prior use of systemic chemotherapy for the treatment of adenocarcinoma of the pancreas (with the exception of gemcitabine, fluorouracil, or capecitabine in the adjuvant setting).
- •2. Any of the following laboratory abnormalities:
- •a. Absolute neutrophil count (ANC) <1,5 x 109/L
- •b. Platelet count <100 x 109/L
- •c. Serum creatinine >2,0 mg/dL (SI units > 177 µmol/L)
- •d. Serum-AST or ALT >3 x upper limit of normal (ULN); in case of liver metastases > 5 x ULN.
- •e. Serum total bilirubin > 3 x ULN
- •f. Haemoglobin < 90 g/L
- •3. Prior history of malignancy within 5 years (except basal or squamous cell carcinoma or carcinoma in situ of the cervix or breast, localized prostate cancer with PSA < 1,0 mg/dL).
- •4. Subjects with a history of or active DVT or PE that are not therapeutically managed on a stable dose of appropriate anticoagulant.
- •5. Brain metastases (subjects that are asymptomatic and do not require steroid control may be enrolled at the discretion of the investigator).
- •6. Surgery within 28 days prior to cycle 1 Day 1 (minimally invasive procedures for the purpose of diagnosis or staging of the disease are permitted, including stent placement and insertion of central venous access advice).
- •7. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- •8. Any serious medical condition or psychiatric illness that places the subject at an unacceptable risk for study participation or would prevent the subject from signing the informed consent form.
- •9. Prior therapy with lenalidomide or thalidomide.
- •10. Use of any other experimental drug or therapy within 28 days prior to Cycle 1 Day 1.
- •11. Pregnant or lactating females.
研究者
相似试验
已完成
1 期
Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic CancerPancreatic Carcinoma MetastaticPancreatic Ductal AdenocarcinomaNCT01547260Maria Liljefors34
进行中（未招募）
不适用
Phase I/II study of lenalidomide and Cetuximab in patients with advanced solid tumorsAdvanced solid tumorsMedDRA version: 9.1Level: LLTClassification code 10065252Term: Solid tumorMedDRA version: 9.1Level: LLTClassification code 10065147Term: Malignant solid tumorEUCTR2009-013423-31-ATMedizinische Universität Innsbruck, Universitätsklinik für Innere Medizin I
进行中（未招募）
1 期
A phase I-II trial of lenalidomide, bendamustin and dexamethasone in the treatment of patients with systemic AL-amyloidosis and ineligible for stem cell transplantation - LeBenDAL-amyloidoseEUCTR2008-007125-39-ATKlinik f. Innere Med., Fachabteilung Hämatologie12
进行中（未招募）
不适用
Phase II study of the combination of Lenalidomide and Alemtuzumab as consolidation in patients who responded to a previus chemotherapeutic regimen administered for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) - len-camCLL patientsMedDRA version: 9.1Level: LLTClassification code 10008958Term: Chronic lymphocytic leukaemiaEUCTR2008-001823-71-ITAssociazione Malattie Sangue ONLUS
进行中（未招募）
不适用
Phase I/II Trial of Lenalidomide in Combination with Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients with Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL)EUCTR2008-006919-20-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH